glp-1 receptor agonists as Treatments for Type 2 Diabetes adverse effects of glp-1 receptor
Description
Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials
Abstract Objectives Glucagon-like peptide 1 (GLP-1) receptor agonists have recently proven to be an effective treatment for type 2 diabetes mellitus (T2DM)
89 In vitro, high glucose increased the expression of inflammasome recombinant NLR Family, pyrin domain containing protein 3 (NLRP3) markers in hippocampal cells
EMA: While the FDA granted Wegovy an additional indication for CV risk reduction, the EMA did not deem this necessary and only added SELECT data to its label
Tirzepatide for Metabolic DysfunctionAssociated Steatohepatitis with Liver Fibrosis
